Literature DB >> 33895745

The Primary Ciliary Dyskinesia Computed Tomography Score in Adults with Bronchiectasis: A Derivation und Validation Study.

Jessica Rademacher1, Sabine Dettmer2, Jan Fuge3, Jens Vogel-Claussen2, Hoen-Oh Shin2, Anand Shah4, Paula Inês Pedro5, Rob Wilson4, Tobias Welte1, Frank Wacker2, Michael R Loebinger4, Felix C Ringshausen1.   

Abstract

BACKGROUND: Primary ciliary dyskinesia (PCD) is a rare genetic disorder which requires a complex diagnostic workup. Thus, an easy and widely available screening method would be helpful to identify patients who need a further diagnostic workup for PCD.
OBJECTIVES: The aim of the study was to develop and validate a computed tomography (CT) score for PCD to facilitate etiological diagnosis in adults with bronchiectasis.
METHOD: Chest CTs from 121 adults with bronchiectasis were scored for bronchiectasis morphology, distribution, and associated findings. Patients with and without the etiological diagnosis of PCD (46 and 75, respectively) were compared. Significantly, different imaging findings (p < 0.05) in univariate analysis were considered for multivariate analysis. Distinct findings were used to build the score. Based on this score, receiver operating characteristic (ROC) curve analysis was performed. The score was validated with 2 independent cohorts, another cohort from the same institution with 56 patients (28 with PCD) and an external cohort from another referral center with 172 patients (86 with PCD).
RESULTS: The following parameters predicted PCD in adults with bronchiectasis and were included in the score with weighting according to their regression coefficients: 2 points were given for predominance in the middle/lower lobe, 2 points for tree-in-bud pattern, 2 points for atelectasis or prior resection of a middle/lower lobe, and 3 points for absence of emphysema and fibrosis. Situs inversus was only observed in subjects with PCD (Kartagener syndrome) and, thus, was not used in the primary ciliary dyskinesia computed tomography (PCD-CT) score as group comparisons could not be performed. ROC curve analysis revealed an area under the curve (AUC) of 0.90 (95% CI 0.85-0.96). Youden index was the highest at a threshold of >6 with a sensitivity of 83% and a specificity of 83%. In the validation cohorts, ROC curve analysis confirmed the performance of the score with an AUC of 0.83 (95% CI 0.72-0.94) in the first validation cohort and 0.79 (95% CI 0.73-0.86) in the external validation cohort.
CONCLUSIONS: The PCD-CT score provides the first validated CT score for PCD and helps physicians in identifying adult bronchiectasis patients who require further diagnostic workup. Key message: The PCD-CT score provides the first validated CT score to assist physicians in identifying adult bronchiectasis patients who require a further diagnostic workup for PCD. It potentially improves earlier recognition of this rare and underdiagnosed disease.
© 2021 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Bronchiectasis; Clinical decision rule; Computed tomography; Kartagener syndrome; Primary ciliary dyskinesia

Mesh:

Year:  2021        PMID: 33895745      PMCID: PMC8220914          DOI: 10.1159/000514927

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  38 in total

1.  Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.

Authors:  Timothy R Aksamit; Anne E O'Donnell; Alan Barker; Kenneth N Olivier; Kevin L Winthrop; M Leigh Anne Daniels; Margaret Johnson; Edward Eden; David Griffith; Michael Knowles; Mark Metersky; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Betsy Carretta; Charles L Daley
Journal:  Chest       Date:  2016-11-23       Impact factor: 9.410

2.  Accuracy of High-Speed Video Analysis to Diagnose Primary Ciliary Dyskinesia.

Authors:  Bruna Rubbo; Amelia Shoemark; Claire L Jackson; Robert Hirst; James Thompson; Joseph Hayes; Emily Frost; Fiona Copeland; Claire Hogg; Christopher O'Callaghan; Isabel Reading; Jane S Lucas
Journal:  Chest       Date:  2019-02-28       Impact factor: 9.410

3.  Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Adam J Shapiro; Stephanie D Davis; Deepika Polineni; Michele Manion; Margaret Rosenfeld; Sharon D Dell; Mark A Chilvers; Thomas W Ferkol; Maimoona A Zariwala; Scott D Sagel; Maureen Josephson; Lucy Morgan; Ozge Yilmaz; Kenneth N Olivier; Carlos Milla; Jessica E Pittman; M Leigh Anne Daniels; Marcus Herbert Jones; Ibrahim A Janahi; Stephanie M Ware; Sam J Daniel; Matthew L Cooper; Lawrence M Nogee; Billy Anton; Tori Eastvold; Lynn Ehrne; Elena Guadagno; Michael R Knowles; Margaret W Leigh; Valery Lavergne
Journal:  Am J Respir Crit Care Med       Date:  2018-06-15       Impact factor: 21.405

4.  A longitudinal study characterising a large adult primary ciliary dyskinesia population.

Authors:  Anand Shah; Amelia Shoemark; Stephanie J MacNeill; Basrull Bhaludin; Andrew Rogers; Diana Bilton; David M Hansell; Robert Wilson; Michael R Loebinger
Journal:  Eur Respir J       Date:  2016-06-10       Impact factor: 16.671

Review 5.  Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome.

Authors:  Margaret W Leigh; Jessica E Pittman; Johnny L Carson; Thomas W Ferkol; Sharon D Dell; Stephanie D Davis; Michael R Knowles; Maimoona A Zariwala
Journal:  Genet Med       Date:  2009-07       Impact factor: 8.822

6.  Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity.

Authors:  Sara Lonni; James D Chalmers; Pieter C Goeminne; Melissa J McDonnell; Katerina Dimakou; Anthony De Soyza; Eva Polverino; Charlotte Van de Kerkhove; Robert Rutherford; John Davison; Edmundo Rosales; Alberto Pesci; Marcos I Restrepo; Antoni Torres; Stefano Aliberti
Journal:  Ann Am Thorac Soc       Date:  2015-12

7.  Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement.

Authors:  Gary S Collins; Johannes B Reitsma; Douglas G Altman; Karel G M Moons
Journal:  BMC Med       Date:  2015-01-06       Impact factor: 8.775

8.  The EMBARC European Bronchiectasis Registry: protocol for an international observational study.

Authors:  James D Chalmers; Stefano Aliberti; Eva Polverino; Montserrat Vendrell; Megan Crichton; Michael Loebinger; Katerina Dimakou; Ian Clifton; Menno van der Eerden; Gernot Rohde; Marlene Murris-Espin; Sarah Masefield; Eleanor Gerada; Michal Shteinberg; Felix Ringshausen; Charles Haworth; Wim Boersma; Jessica Rademacher; Adam T Hill; Timothy Aksamit; Anne O'Donnell; Lucy Morgan; Branislava Milenkovic; Leandro Tramma; Joao Neves; Rosario Menendez; Perluigi Paggiaro; Victor Botnaru; Sabina Skrgat; Robert Wilson; Pieter Goeminne; Anthony De Soyza; Tobias Welte; Antoni Torres; J Stuart Elborn; Francesco Blasi
Journal:  ERJ Open Res       Date:  2016-01-20

9.  Prevalence and course of disease after lung resection in primary ciliary dyskinesia: a cohort & nested case-control study.

Authors:  Panayiotis Kouis; Myrofora Goutaki; Florian S Halbeisen; Ifigeneia Gioti; Nicos Middleton; Israel Amirav; Angelo Barbato; Laura Behan; Mieke Boon; Nagehan Emiralioglu; Eric G Haarman; Bulent Karadag; Cordula Koerner-Rettberg; Romain Lazor; Michael R Loebinger; Bernard Maitre; Henryk Mazurek; Lucy Morgan; Kim Gjerum Nielsen; Heymut Omran; Ugur Özçelik; Mareike Price; Andrzej Pogorzelski; Deborah Snijders; Guillaume Thouvenin; Claudius Werner; Zorica Zivkovic; Claudia E Kuehni; Panayiotis K Yiallouros
Journal:  Respir Res       Date:  2019-09-18

10.  Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia.

Authors:  Helene E Kobbernagel; Frederik F Buchvald; Eric G Haarman; Carmen Casaulta; Samuel A Collins; Claire Hogg; Claudia E Kuehni; Jane S Lucas; Heymut Omran; Alexandra L Quittner; Claudius Werner; Kim G Nielsen
Journal:  BMC Pulm Med       Date:  2016-07-22       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.